Related Experiment Video

Updated: Feb 4, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K

Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia

Cinzia Bologna1,2, Silvia Deaglio1,2

  • 1Department of Medical Sciences, University of Torino, Italy.

Molecular & Cellular Oncology
|September 26, 2018
PubMed

Insights

Loss of signaling lymphocytic activation molecule family 1 (SLAMF1) in chronic lymphocytic leukemia (CLL) correlates with shorter survival. This loss also reduces the effectiveness of autophagy-inducing drugs, impacting treatment options for CLL patients.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Signaling lymphocytic activation molecule family 1 (SLAMF1), also known as CD150, is a costimulatory molecule and microbial sensor.
  • SLAMF1 expression is notably absent in chronic lymphocytic leukemia (CLL) patients with poorer prognoses.
  • SLAMF1 plays a role in modulating CLL cell responses to chemokines and regulating autophagy.

Purpose of the Study:

  • To investigate the functional consequences of SLAMF1 loss in chronic lymphocytic leukemia (CLL).
  • To determine the impact of SLAMF1 expression on CLL cell sensitivity to autophagy-inducing therapies.

Main Methods:

  • Analysis of SLAMF1 expression in CLL patient cohorts.
  • Assessment of chemokine responses in CLL cells with varying SLAMF1 levels.
  • Evaluation of autophagy regulation and drug sensitivity in SLAMF1-deficient CLL cells.

Main Results:

  • Reduced overall survival was observed in CLL patients with absent SLAMF1 expression.
  • Loss of SLAMF1 impairs the regulation of autophagy in CLL cells.
  • CLL cells lacking SLAMF1 exhibit diminished responsiveness to autophagy-inducing drugs, including B-cell CLL/lymphoma 2 (BCL2) inhibitors.

Conclusions:

  • SLAMF1 expression is a significant prognostic marker in CLL, with its loss associated with adverse outcomes.
  • The absence of SLAMF1 impacts critical cellular processes like autophagy, potentially conferring resistance to targeted therapies.
  • Targeting SLAMF1 or understanding its role in drug resistance may offer new therapeutic strategies for CLL.
Keywords:
AutophagyCLLSLAMF1

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.9K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.6K
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
58.8K
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
109.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.6K